A case of xenon inhalation therapy for respiratory failure and neuropsychiatric disorders associated with COVID-19
Authors:
- Vladimir Vasil'EVich UdutVUVladimir Vasil'EVich Udut
- Sergei Alexandrovich NaumovSNSergei Alexandrovich Naumov
- Diana Nikolaevna EvtushenkoDEDiana Nikolaevna Evtushenko
- Elena Vladimirovna UdutEUElena Vladimirovna Udut
- Sergei Sergeevich NaumovSNSergei Sergeevich Naumov
- Gleb Nikolaevich Zyuz'KOvGZGleb Nikolaevich Zyuz'KOv
Open Access
- 28 October 2021
- journal article
- research article
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 20, 1517-1525
Abstract
Acute respiratory distress syndrome (ARDS) is the main danger to the life of patients with pneumonia caused by SARS-CoV-2. At the same time, respiratory failure (RF) after ARDS can persist for a long time despite intensive therapy. Therefore, it is important to develop new effective approaches for restoring the ventilation function of the lungs after COVID-19. Here, we present a case report of effective application of short-term inhalations of xenon-oxygen (Xe/O2) gas mixture for treatment of RF and neuropsychiatric disorders (NPD) associated with COVID-19. The patient inhaled a gas mixture of 70 % Xe and 30 % O2. We used multispiral computed tomography, evaluated psychometry, studied hematological and biochemical blood parameters, and applied some other methods of clinical studies to assess the therapeutic effectiveness of Xe inhalation. Also, we studied the mechanism of action of xenon with computer modeling. The clinical case showed the high efficacy of Xe/O2 mixture for treating severe RF and NPD after SARS-CoV-2 infection. Xenon inhalations dramatically increased oxygen saturation and the degree of pneumatization of the lungs. We found out that in coronavirus pneumonia, saturated phospholipids of surfactant are transferred to the solid-ordered phase, which disrupts the surface tension of the alveoli and alveolar gas exchange. Using molecular modeling methods, we demonstrated that the xenon atom increases the distance between the acyl chains of phospholipids due to the van der Waals dispersion interaction. These changes allow for the phase transition of phospholipids from the solid-ordered phase to the liquid phase and restore the functional activity of the surfactant. The findings suggest the feasibility of conducting studies on the effectiveness of Xe/O2 inhalations for treating ARDS in SARS-CoV-2 infection.Keywords
This publication has 31 references indexed in Scilit:
- Psychological status of medical workforce during the COVID-19 pandemic: A cross-sectional studyPsychiatry Research, 2020
- The trinity of COVID-19: immunity, inflammation and interventionNature Reviews Immunology, 2020
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challengesInternational Journal of Antimicrobial Agents, 2020
- The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patientsJournal of Medical Virology, 2020
- Xenon produces rapid antidepressant- and anxiolytic-like effects in lipopolysaccharide-induced depression mice modelNeuroReport, 2020
- Clinical utility of the Epworth sleepiness scaleSleep and Breathing, 2020
- Neuroprotective Properties of XenonMolecular Neurobiology, 2019
- Tailoring van der Waals dispersion interactions with external electric chargesNature Communications, 2018
- Xenon in the treatment of panic disorder: an open label studyJournal of Translational Medicine, 2017
- Lung surfactant: Function and composition in the context of development and respiratory physiologyAnnals of Anatomy - Anatomischer Anzeiger, 2016